Sipuleucel-T, marketed as Provenge and developed by Dendreon Pharmaceuticals, is a cell-based cancer immunotherapy used to treat prostate cancer. It is classed as an autologous cellular immunotherapy, meaning it is manufactured from a patient's own immune cells before being returned to that same patient.
Facts
Sources
1. Wikipedia
Wikipedia contributors, Wikimedia Foundationhttps://en.wikipedia.org/wiki/Sipuleucel-T, lead sectionQuote, https://en.wikipedia.org/wiki/Sipuleucel-T, lead section
Sipuleucel-T, sold under the brand name Provenge, developed by Dendreon Pharmaceuticals, LLC, is a cell-based cancer immunotherapy for prostate cancer (CaP).
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.